219 related articles for article (PubMed ID: 18431480)
1. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.
Roukens AH; Vossen AC; Bredenbeek PJ; van Dissel JT; Visser LG
PLoS One; 2008 Apr; 3(4):e1993. PubMed ID: 18431480
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.
Roukens AHE; van Halem K; de Visser AW; Visser LG
Ann Intern Med; 2018 Dec; 169(11):761-765. PubMed ID: 30476963
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
Juan-Giner A; Kimathi D; Grantz KH; Hamaluba M; Kazooba P; Njuguna P; Fall G; Dia M; Bob NS; Monath TP; Barrett AD; Hombach J; Mulogo EM; Ampeire I; Karanja HK; Nyehangane D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
Lancet; 2021 Jan; 397(10269):119-127. PubMed ID: 33422245
[TBL] [Abstract][Full Text] [Related]
4. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Kimathi D; Juan-Giner A; Orindi B; Grantz KH; Bob NS; Cheruiyot S; Hamaluba M; Kamau N; Fall G; Dia M; Mosobo M; Moki F; Kiogora K; Chirro O; Thiong'o A; Mwendwa J; Guantai A; Karanja HK; Gitonga J; Mugo D; Ramko K; Faye O; Sanders EJ; Grais RF; Bejon P; Warimwe GM
Lancet Infect Dis; 2023 Aug; 23(8):974-982. PubMed ID: 37127045
[TBL] [Abstract][Full Text] [Related]
6. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
[TBL] [Abstract][Full Text] [Related]
7. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.
Roukens AH; Soonawala D; Joosten SA; de Visser AW; Jiang X; Dirksen K; de Gruijter M; van Dissel JT; Bredenbeek PJ; Visser LG
PLoS One; 2011; 6(12):e27753. PubMed ID: 22163273
[TBL] [Abstract][Full Text] [Related]
8. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.
Jia Q; Jia C; Liu Y; Yang Y; Qi J; Tong L; Chen H; Zhang M; Che J; Li B; Li Z
Antiviral Res; 2019 Feb; 162():1-4. PubMed ID: 30529359
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.
Casey RM; Harris JB; Ahuka-Mundeke S; Dixon MG; Kizito GM; Nsele PM; Umutesi G; Laven J; Kosoy O; Paluku G; Gueye AS; Hyde TB; Ewetola R; Sheria GKM; Muyembe-Tamfum JJ; Staples JE
N Engl J Med; 2019 Aug; 381(5):444-454. PubMed ID: 29443626
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Juan-Giner A; Namulwana ML; Kimathi D; Grantz KH; Fall G; Dia M; Bob NS; Sall AA; Nerima C; Sahani MK; Mulogo EM; Ampeire I; Hombach J; Nanjebe D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
Lancet Infect Dis; 2023 Aug; 23(8):965-973. PubMed ID: 37127047
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
[TBL] [Abstract][Full Text] [Related]
12. Yellow fever vaccine: past, present and future.
Roukens AH; Visser LG
Expert Opin Biol Ther; 2008 Nov; 8(11):1787-95. PubMed ID: 18847312
[TBL] [Abstract][Full Text] [Related]
13. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
16. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
Barrett AD; Teuwen DE
Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
[TBL] [Abstract][Full Text] [Related]
17. Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.
Kareko BW; Booty BL; Nix CD; Lyski ZL; Slifka MK; Amanna IJ; Messer WB
J Infect Dis; 2020 Jun; 221(12):2018-2025. PubMed ID: 31545367
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
19. Duration of post-vaccination humoral immunity against yellow fever in children.
de Noronha TG; de Lourdes de Sousa Maia M; Geraldo Leite Ribeiro J; Campos Lemos JA; Maria Barbosa de Lima S; Martins-Filho OA; Campi-Azevedo AC; da Silva Freire M; de Menezes Martins R; Bastos Camacho LA;
Vaccine; 2019 Nov; 37(48):7147-7154. PubMed ID: 31590934
[TBL] [Abstract][Full Text] [Related]
20. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.
Julander JG; Trent DW; Monath TP
Vaccine; 2011 Aug; 29(35):6008-16. PubMed ID: 21718741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
